No abstract

p<0.001) and chemotherapy (12.6% vs 1.9%, p<0.001). Admission to the intensive care unit (ICU) was significantly more frequent in surgical patients (35.4% vs 10.9%, p<0.001) as well as use of second and third generation cephalosporins (30.0% vs 17.6%, p=0.001; 64.6% vs 53.1%, p=0.007, respectively). Conclusion and relevance Age !65 years, use of PPIs, chemotherapy and fluoroquinolones were positively associated with the medical group and were significant predictors of CDI, whereas admission to the ICU and the use of second and third generation cephalosporins were positively associated with being in the surgical group and were significant predictors of CDI. We conclude that medical patients were more endangered with HA CDI than surgical patients.

in 2.6%. At least 41% of the patients had been treated with PPIs for more than a year; for the rest of the patients, no prescription data were available prior to joining the pharmacy service. The mean number of drugs prescribed per patient was 8.3±5, 1.2% were being treated with an NSAID, 42.3% were taking acetylsalicylic acid concomitantly at antiplatelet doses and 3.8% were given bisphosphonates. The prevalence of patients being treated with a PPI and with a history of fracture was 48.7%. Conclusion and relevance There was a high prevalence of patients without a clear indication for the prescription of PPIs in the GHC. This makes it necessary to review the treatments to assess possible deprescription of these drugs. In addition, their administration could be related to an increased risk of fractures due to its high prevalence.

Background Lysosomal acid lipase deficiency (LALD) is a rare lysosomal disorder characterised by clinical with dyslipidaemia and steatohepatitis. Sebelipase-alfa is a recombinant human LAL, recently approved for clinical use in LALD. Purpose Evaluation of the effectiveness and safety of sebelipase-alfa as enzyme replacement therapy in paediatric patients with LALD. Material and methods Observational, retrospective study included three patients treated with sebelipase-alfa. From clinical history the following data were obtained: age, sex, diagnosis, values of total cholesterol, low-density lipoprotein